Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
Public ClinicalTrials.gov record NCT02162420. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell transplant using related or unrelated donor in persons 0-70 years of age diagnosed with dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized by a requirement for red blood cell and platelet transfusions. Three different preparative regimens are included based on disease and donor type.
Study identification
- NCT ID
- NCT02162420
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Interventions
- Alemtuzumab Drug
- Fludarabine Drug
- Cyclophosphamide Drug
- Total Body Irradiation Radiation
- Stem Cell Transplant Biological
- Anti-thymocyte globulin Drug
Drug · Radiation · Biological
Eligibility (public fields only)
- Age range
- 0 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 9, 2015
- Primary completion
- Aug 7, 2024
- Completion
- Mar 10, 2025
- Last update posted
- May 7, 2025
2015 – 2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Minnesota Medical Center, Fairview | Minneapolis | Minnesota | 55455 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Dyskeratosis Congenita trials
Other public records listing Dyskeratosis Congenita. Sorted by last update posted; newest first. Not a recommendation.
- NCT07628972: Quercetin Dyskeratosis Congenita (DC)/Telomere Biology Disorders (TBD) Recruiting
- NCT00027274: Cancer in Inherited Bone Marrow Failure Syndromes Recruiting
- NCT03050268: Familial Investigations of Childhood Cancer Predisposition Recruiting
- NCT01659606: Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita Active, not recruiting
- NCT06817590: Nucleoside Therapy in Patients With Telomere Biology Disorders Recruiting
- NCT03579875: Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02162420, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2025 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02162420 live on ClinicalTrials.gov.